AJNN

The Academic Journal of Neurology and Neurosurgery deals with Neurology and Neurosurgery accepts articles on these topics. Academic Journal of Neurology and Neurosurgery publishes original research articles, review articles, case reports, editorial commentaries, letters to the editor, educational articles, and conference/meeting announcements.

EndNote Style
Index
Review
Are gabapentinoids addictive?
Gabapentinoids are highly effective drugs used in the treatment of epilepsy, anxiety disorders, and particularly neuropathic pain. In recent years, their use has become a cause for concern as reports on their misuse have increased. Studies have been conducted to identify the patient groups that are prone to the drug’s misuse. Additionally, the drug’s use has been restricted in some countries. While gabapentinoids are favored due to their efficacy in pain management, their potential for addiction has made them a drug that physicians are increasingly hesitant to prescribe. The aim of this study is to review the research on the addictive effects of gabapentinoids, providing physicians with information on predictive tests and anamnesis data regarding the risk of addiction.


1. Chan AYL, Yuen ASC, Tsai DHT, et al. Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study. Nat Commun. 2023;14(1):5005. doi:10.1038/s41467-023-40637-8
2. Gulec G, Kosger F, Essizoglu A. Alcohol and substance use disorders in DSM-5. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry. Published online 2015. doi:10.5455/cap.20150325081809
3. Maldonado R, Calvé P, García-Blanco A, Domingo-Rodriguez L, Senabre E, Martín-García E. Vulnerability to addiction. Neuropharmacology. 2021;186:108466. doi:10.1016/j.neuropharm.2021.108466
4. Reed B, Kreek MJ. Genetic vulnerability to opioid addiction. Cold Spring Harb Perspect Med. 2021;11(6):a039735. doi:10.1101/cshperspect.a039735
5. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-426. doi:10.1007/s40265-017-0700-x
6. Athavale A, Murnion B. Gabapentinoids: a therapeutic review. Aust Prescr. 2023;46(4):80-85. doi:10.18773/austprescr.2023.025
7. Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104-114. doi:10.1177/2049463720912496
8. McAnally H, Bonnet U, Kaye AD. Gabapentinoid benefit and risk stratification: mechanisms over myth. Pain Ther. 2020;9(2):441-452. doi:10.1007/s40122-020-00189-x
9. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28(6):491-496. doi:10.1007/s40263-014-0164-4
10. Althobaiti YS, Almalki A, Alsaab H, et al. Pregabalin: potential for addiction and a possible glutamatergic mechanism. Sci Rep. 2019;9(1): 15136. doi:10.1038/s41598-019-51556-4
11. Stannard C. Misuse of gabapentin and pregabalin: a marker for a more serious malaise? Addiction (Abingdon, England). 2016;111(10):1699-1700. doi:10.1111/add.13408
12. Schjerning O, Rosenzweig M, Pottegård A, Damkier P, Nielsen J. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016;30(1):9-25. doi:10.1007/s40263-015-0303-6
13. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27(12):1185-1215. doi:10.1016/j.euroneuro.2017.08.430
14. Darke S, Duflou J, Peacock A, Farrell M, Lappin J. Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000-2020. Clin Toxicol. 2022;60(3):304-310. doi:10.1080/15563650.2021.1965159
15. Erden Y, Kaya SS, Okçu M. Pregabalin and gabapentin use disorders. Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi. 2019;22(3):126-133. doi: 10.31609/jpmrs.2019-66052
16. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother. 2016;50(3):229-233. doi:10.1177/ 1060028015620800
17. Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psychiatry. 2021;12:639780. doi:10. 3389/fpsyt.2021.639780
18. Grosshans M, Lemenager T, Vollmert C, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69(12):2021-2025. doi:10.1007/s00228-013-1578-5
19. Antunovic M, Vucinic S, Kotur-Stevuljevic J, et al. Rise of pregabalin poisoning and abuse cases in Serbia: a ten-year retrospective study. Int J Gen Med. 2023;16:1239-1250. doi:10.2147/IJGM.S405616
20. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432-442. doi:10.1111/j.1526-4637.2005.00072.x
21. Warlick H, Leon L, Patel R, et al. Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model. Mol Biol Rep. 2023;50(2):1765-1784. doi:10.1007/s11033-022-08110-9
22. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26(4):461-470. doi:10.1177/0269881111405360
23. Wills B, Reynolds P, Chu E, et al. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10(3):254-260. doi:10.1007/s13181-014-0384-5
24. Novotny M, Bulla J, Hubl D, et al. Pregabalin use in forensic hospitals and prisons in German speaking countries—a survey study of physicians. Front Public Health. 2024;11:1309654. doi:10.3389/fpubh.2023.1309654
25. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10): e1002396. doi:10.1371/journal.pmed.1002396
26. Powell D, Shetty KD, Peet ED. Trends in overdose deaths involving gabapentinoids and Z-drugs in the United States. Drug Alcohol Depend. 2023;249:109952. doi:10.1016/j.drugalcdep.2023.109952
27. Kuo YF, Polychronopoulou E, Raji MA. Signal detection of adverse events associated with gabapentinoid use for chronic pain. Pharmacoepidemiol Drug Saf. 2024;33(1):e5685. doi:10.1002/pds.5685
Volume 2, Issue 1, 2025
Page : 9-12
_Footer